Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreemen...
Clinical Microbiomics A/S^1, the global microbiome science company, announces the acquisition of DNASense ApS, an innovative Danish microbiome C...
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that...
BeiGene, Ltd. announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed...
-Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, announced the launch of DiscoveryAI SAFIRE (Suite o...
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...
Global license and collaboration agreement set to advance the development of OSE-230, a monoclonal antibody aimed at resolving chronic inflammation. ...
Bristol Myers Squibb (NYSE: BMY) announced that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the ...
Fujifilm Irvin Technology is a leader in the innovation and manufacturing of cell culture solutions in the global life sciences and medical markets. With t...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimil...
Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...
LimmaTech Biologics AG, announced encouraging interim results from its Phase I/II clinical trial evaluating Shigella4V (S4V), a promising tetravalent bioco...
© 2025 Biopharma Boardroom. All Rights Reserved.
